Synlait Milk, the Canterbury milk processor controlled by China’s Bright Dairy, has signed a deal to supply colostrum to ASX-listed biopharmaceutical company Immuron.
No value was put on the agreement.
A spokesman for Synlait said his company planned a production run of the ‘hyperimmune colostrum’ in October. While the volumes would be small compared to Synlait’s total production, it was high-end in terms of value, said Synlait spokesman Michael Wan.
Immuron, which focusses on “oral immunotherapy treatments using dairy-derived antibody products for humans”, has a product for the prevention of diarrhoea, Travelan, on the market and several others in various stages of development, according to its statement.
“As Immuron embarks on an era of increased global distribution of Travelan and other products, it is imperative to have a partner able to accommodate the anticipated significant increase in supply capacity, chief executive Joe Baini said in the statement.
Shares of Immuron rose 5.9 percent to 1.8 Australian cents on the ASX today and have declined 66 percent this year.
Last month, the Melbourne-based company raised A$2 million via a A$1 million share placement and an underwritten A$1 million share purchase plan. Proceeds were to fund the rollout of Travelan and ongoing development of other products, it said at the time.
(BusinessDesk)
1 Comments
Yes the art of the press release, probably not much the boys from Dunsandel could learn from their best new friends in that dept.
http://www.asx.com.au/asxpdf/20120507/pdf/4263bysh4887h7.pdf
Synlait is an innovative dairy processing company based in Canterbury, New Zealand. It specialises in producing infant formula and adult nutritional formulations, functional food ingredients and specialised products to support a healthy lifetsyle. Synlait's production systems feature the latest technology and have fully integrated and controlled systems. For instance, Synlait controls tight calving patterns and has its own in-house veterinary capabilities which results in Synlait being able to deliver significant efficiencies with economies of scale....
But we do appreciate the humour from the BusinessDesk: "No value was put on the the agreement".
We welcome your comments below. If you are not already registered, please register to comment.
Remember we welcome robust, respectful and insightful debate. We don't welcome abusive or defamatory comments and will de-register those repeatedly making such comments. Our current comment policy is here.